The triggering receptor expressed on myeloid cells 2 (TREM2) plays a pivotal role in the activation of myeloid cells and is currently being investigated as a potential therapeutic target in several ...

The NOX-targeted therapy market is expected to expand significantly over the upcoming years as more therapies move into ...

Lung macrophages play a pivotal role in diseases like idiopathic pulmonary fibrosis. Two types of macrophages—the white blood ...

When the macrophages’ ability to consume dying cancer cells or Upd3 production was decreased, tumor growth was significantly ...

This important study looks into the effect of exogenous CoA on the response of TLR4-activated macrophages. Specifically, CoA enhances the LPS response by examining metabolomics, 13C tracing, and ...

The FDA has approved Gamifant as the first-ever treatment for macrophage activation syndrome in Still’s disease for adults ...

A receptor on macrophages dictated their ability to reduce inflammation after liver transplant, offering potential ...

Glucan-mediated trained immunity activates alveolar macrophages which exacerbates acute lung injury induced by LPS.

Human exposure to toxic particles drives various diseases. Examples include gout, an acute arthritis driven by monosodium urate crystals, or MSUc; CPPD disease, another inflammatory joint disease ...

Tissue macrophages in this region exert immune homeostatic function by capturing antigens, protecting sympathetic nerves and limiting neutrophil recruitment upon inflammation.

Emapalumab is approved for both adults and pediatric (newborn and older) patients with MAS in Still disease with an inadequate response or intolerance to glucocorticoids, or with recurrent MAS.